Every flu vaccine sold in the United States for the past eight decades has been grown in fertilized chicken eggs. That changed Wednesday. The FDA approved mFLUSIVA (mRNA-1010) for all adults 50 and older — the first influenza shot licensed in the US on messenger RNA, and Moderna’s fourth approved product after two COVID vaccines and one for RSV.
The agency split the decision by age. For adults 50 to 64, standard full approval on clinical efficacy data. For 65 and older, accelerated approval — licensure on a surrogate endpoint, with a required postmarketing confirmatory trial. Moderna says the shot should reach select US retailers within weeks and go wide for the 2026–2027 respiratory season.
The efficacy case rests on FLUENT, a Phase 3 trial that enrolled 40,805 adults 50 and older across 301 sites in 11 countries during the 2024–25 season, randomized one-to-one against a licensed standard-dose comparator. Relative vaccine efficacy against PCR-confirmed influenza-like illness: 26.6%, with a 95% confidence interval of 16.7% to 35.4%. In absolute terms, 2.0% of mFLUSIVA recipients got sick versus 2.8% on the standard shot. Narrow to the outcomes that cost money — ER visits, hospitalizations, urgent care — and relative efficacy rises to 47.9%. The FDA’s advisory panel voted 9–0 in favor.
Our take: Approval is the easy half. In US vaccines, the money gate is not the FDA — it is the CDC’s Advisory Committee on Immunization Practices, because the ACA only obliges private insurers to cover a vaccine at zero cost once ACIP recommends it. A federal district court in Massachusetts stayed the reconstituted committee in March 2026 after the wholesale replacement of all 17 sitting members; the government’s appeal is still pending before the First Circuit, and the next scheduled meeting is October. So the first mRNA flu shot in American history has arrived into a regulatory system with its recommending body switched off. Insurers may cover it voluntarily and many probably will. Nobody has to. If you are 50-plus and interested, call your plan before you book — that is not a caveat, it is the actual state of play this fall.
The tradeoff Moderna has to sell
Reactogenicity is the well-documented cost. Injection-site pain hit 65.8% of mFLUSIVA recipients against 29.8% on the comparator. Fatigue: 45.1% versus 20.3%. Headache: 37.8% versus 18.0%. Predominantly mild to moderate, mostly resolved inside one to two days — and still roughly double the unpleasantness of the shot people already skip.
Serious adverse events were comparable across arms, 2.2% versus 1.9%, with no reported myocarditis or pericarditis. Advisory committee members were blunt about the marketing problem this creates. “We really need to be able to message why people should get this vaccine,” Baylor’s Dr. Hana El Sahly told the panel. A sorer arm for a better outcome is a rational trade and a hard sell, in that order.
The 65-plus question is genuinely open
For older adults the relevant benchmark is not a standard-dose shot. It is Fluzone High-Dose, which the CDC preferentially recommends for the 65-plus cohort and which packs four times the antigen per strain. That product has clinical endpoint evidence behind it, including a trial of more than 30,000 adults establishing 24.2% greater effectiveness than standard-dose at preventing confirmed influenza.
mFLUSIVA’s 65-plus approval is built on immunogenicity — antibody responses non-inferior to Fluzone High-Dose at day 29 and six months — not a head-to-head hospitalization trial. That trial is the postmarketing commitment: up to 800,000 older adults across two flu seasons, with results expected around 2027 or 2028. Until then, nobody in this age group has evidence telling them to switch.
What the approval quietly unlocks
The strategic value sits downstream. Moderna withdrew its US application for mRNA-1083, the combined COVID-and-flu shot, in May 2025 specifically because the FDA wanted Phase 3 influenza efficacy data first. FLUENT is that data. The combination is already authorized in the EU as mCOMBRIAX — the world’s first licensed COVID-flu combo — which is the awkward fact Moderna has been carrying for a year. No US resubmission timeline has been announced, but the blocking condition is gone.
Same mechanic on pandemic preparedness. When CEPI committed up to $54.3 million in December 2025 to fund the Phase 3 trial of Moderna’s H5 candidate mRNA-1018, it said outright that licensure would leverage data from the mRNA-1010 seasonal trial. First participants were dosed in April. That program exists on non-US-government money after the administration canceled a $760 million BARDA contract in May 2025 and HHS terminated roughly $500 million in further mRNA contracts that August.
What to watch
- October’s ACIP meeting. No lawful recommendation, no coverage mandate, no pharmacy default. This one date governs whether mFLUSIVA is a product or a press release this season.
- The mRNA-1083 resubmission. One annual injection instead of two is the commercial prize, and Europe has been selling it since spring.
- Season-one uptake. Most 2026 flu vaccine purchasing was locked by health systems and pharmacies before Wednesday. Supply is a real constraint, not an excuse.
- The calendar advantage. mRNA runs strain selection to finished vaccine in roughly two to three months against about six for eggs. If H3N2 drifts again this winter, that gap stops being a slide and starts being a number.
Moderna has now proven its platform against a routine, annually recurring disease rather than an emergency — the harder commercial test, and the one that determines whether mRNA is a pandemic tool or an industry. The reimbursement plumbing has not caught up, which is a familiar shape: the science cleared, the payer layer did not, and the patient finds out at the counter.